Closing the Innovation Gap: Why Drug Discovery Breakthroughs Are Failing to Reach Patients
Why do so many drug discovery breakthroughs fail to reach patients? Trisha Pillay speaks with Christian Nkanga to find out.
Insights
In-depth articles and expert analysis from pharmaceutical leaders, exploring advances in life sciences, drug development and the trends shaping healthcare innovation.
Image
The Future for Decentralised Clinical Trials
Image
Reimagine AI-driven Drug Discovery with Pharmaceutical Superintelligence
Image
First Quarter 2026 State of Digital Health Funding
Image
Maximise Pharma Innovation With Quality-by-Design
Image
Digital Twins in Clinical Trials: Simulating Success Before Enrolment
Image
Phenotypic Drug Discovery: Beyond the Target
Image
The Looming Threat of Geopolitical Risk in Clinical Supply Chains
Explore All Insights
Browse our complete library of expert articles and analysis. Explore content across science, policy and life sciences innovation.
The Future for Decentralised Clinical Trials
Decentralised clinical trials promise to transform drug development and pharma strategy. The evidence tells a complex story. Here is what’s working and what still needs to be fixed.
Reimagine AI-driven Drug Discovery with Pharmaceutical Superintelligence
Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.
First Quarter 2026 State of Digital Health Funding
Digital health funding hit $7.4B in Q1 2026, the highest since Q2 2022. The CB Insights State of Digital Health report reveals where capital is concentrating and why it matters for pharma leaders.
Digital Twins in Clinical Trials: Simulating Success Before Enrolment
Digital twins in clinical trials simulate patient outcomes to reduce risk and accelerate timelines. Learn how sponsors use them for predictive trial design.
Phenotypic Drug Discovery: Beyond the Target
Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.
Precision Logistics to Speed Up Clinical Trials
Precision logistics in clinical trials is transforming global study execution through real-time tracking, cold-chain management, and advanced operational visibility.
Cell Therapy for Solid Tumours: Current Challenges and New Advances
Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.
Designing Decentralised Clinical Trials for Patient Diversity
Data shows that most DCT approaches significantly improve patient diversity. This analysis examines what the evidence means for clinical trial design strategy.
Why Precision Alone Isn't Enough in Oncology Drug Discovery
Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.
Selecting the Right Data Collection Method for Real-World Evidence
Choosing the wrong RWE data source undermines your regulatory strategy. This framework helps pharma leaders select the right real-world data collection method based on your programme’s research question.
Drug Discovery and Pharmacoinformatics in 2026
Pharmacoinformatics is redefining drug discovery strategy. This analysis covers the AI platforms, molecular design tools, and regulatory frameworks shaping R&D pipelines in 2026.
Decentralised Clinical Trials: Balancing Innovation and Integrity
Decentralised clinical trials expand access and reduce patient burden. Learn how sponsors balance innovation in DCT design, data integrity, and regulatory compliance.